
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx is a rapidly growing biopharmaceutical company with a strong platform for developing first-in-class medicines to meet unmet medical needs. With its products Ibsrela and Xphozah targeting large patient populations with high unmet needs, Ardelyx has the potential for significant revenue growth. Despite facing reimbursement headwinds, the company remains on solid footing and has the potential to succeed, making it a positive investment opportunity.
Bears say
Ardelyx is facing challenges as their Chief Commercial Officer departs and their recent earnings report reveals a topline miss for Ibsrela and revised guidance for both Ibsrela and Xphozah. This is due to increased payor utilization management, slowing new patient starts, and market dynamics that may impact the potential success of these drugs. The company also has a high discount rate and terminal growth rate, resulting in a lowered price target.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares